USP20 promotes CD8(+) T cell exhaustion and impairs KRAS(G12D) inhibitor efficacy by orchestrating cholesterol metabolism and autophagy in pancreatic cancer.
Targeting one enzyme restored immune function and drug sensitivity in pancreatic cancer models, suggesting a rational combination approach.
Yu et al. show that the deubiquitinase USP20 promotes immune exhaustion of CD8+ T cells in pancreatic ductal adenocarcinoma by coordinating cholesterol synthesis and autophagy in the tumour microenvironment, simultaneously reducing the efficacy of the KRAS G12D inhibitor MRTX1133. Inhibiting USP20 restored T cell function and enhanced KRAS G12D inhibitor activity in preclinical models, identifying USP20 as a rational combination therapy target for PDAC.
What the study was
- Study design
- Mechanistic experimental study (in vitro and in vivo, multiple models)
- Population
- Pancreatic ductal adenocarcinoma preclinical models
- Category
- Drug Development
- Maturity
- Exploratory
- Journal
- Gut
Why it surfaced
Gut publication revealing novel immune-metabolic resistance axis to the KRAS G12D inhibitor class; mechanistically rigorous and relevant to pancreatic cancer immunotherapy combination strategies.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.